Genzyme/Bayer Report Positive Top-Line Phase II MS Data For Campath
This article was originally published in The Pink Sheet Daily
Executive Summary
Clinical hold on the Phase II trial was lifted “within the last six months” and dosing completed, Genzyme’s Enyedy says.